We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

124 hedge funds and large institutions have $149M invested in Rigel Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 37 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,036% more call options, than puts

Call options by funds: $818K | Put options by funds: $72K

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

5% more funds holding

Funds holding: 118 → 124 (+6)

0.18% more ownership

Funds ownership: 6.29% → 6.47% (+0.18%)

5% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 37

9% less capital invested

Capital invested by funds: $163M → $149M (-$14.5M)

Holders
124
Holders Change
+6
Holders Change %
+5.08%
% of All Funds
1.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
35
Reduced
37
Closed
12
Calls
$818K
Puts
$72K
Net Calls
+$746K
Net Calls Change
-$251K

Top Buyers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
+$20.3M
2
Millennium Management
Millennium Management
New York
+$3.26M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.88M
4
UOC
UBS O'Connor
Illinois
+$1.2M
5
Two Sigma Investments
Two Sigma Investments
New York
+$1.07M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.62M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.03M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.72M
4
VOYA Investment Management
VOYA Investment Management
Georgia
-$2.62M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$1.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$22.5M +$108K +6,800 +0.4%
BlackRock
2
BlackRock
New York
$18.6M -$888K -55,890 -4%
SCM
3
Soleus Capital Management
Connecticut
$16.9M +$20.3M +1,280,302 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$15M -$1.15M -72,467 -6%
Millennium Management
5
Millennium Management
New York
$6.91M +$3.26M +204,884 +64%
Jacobs Levy Equity Management
6
Jacobs Levy Equity Management
New Jersey
$4.98M -$872K -54,894 -13%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$4.91M +$289K +18,206 +5%
State Street
8
State Street
Massachusetts
$4.55M +$113K +7,125 +2%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$4.32M +$199K +12,512 +4%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$3.74M -$9.62M -605,569 -68%
N
11
Nuveen
North Carolina
$3.63M +$53.8K +3,386 +1%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$3.12M +$902K +56,770 +32%
Two Sigma Investments
13
Two Sigma Investments
New York
$2.95M +$1.07M +67,233 +43%
TA
14
Tamarack Advisers
California
$2.64M -$477K -30,000 -13%
Renaissance Technologies
15
Renaissance Technologies
New York
$2.61M +$1.88M +118,022 +148%
SFM
16
Sphera Funds Management
Israel
$2.48M -$635K -40,000 -18%
DZ Bank
17
DZ Bank
Germany
$2.41M -$607K -38,204 -17%
Macquarie Group
18
Macquarie Group
Australia
$2.11M – – –
Northern Trust
19
Northern Trust
Illinois
$2.01M +$16K +1,009 +0.7%
CM
20
CM Management
Florida
$1.98M – – –
VOYA Investment Management
21
VOYA Investment Management
Georgia
$1.78M -$2.62M -165,026 -55%
Assenagon Asset Management
22
Assenagon Asset Management
Luxembourg
$1.73M +$766K +48,243 +58%
RPAM
23
Rhenman & Partners Asset Management
Sweden
$1.55M -$107K -6,749 -6%
Charles Schwab
24
Charles Schwab
California
$1.14M +$104K +6,562 +8%
UOC
25
UBS O'Connor
Illinois
$1,000K +$1.2M +75,751 New
1
2 3 4 5

RIGL Hedge Fund Activity: Q1 2023 in Review

124 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2023, worth a combined $149M — down 8.9% from $163M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RIGL positions and 12 closed out — a net gain of 7 holders — while 35 added to existing stakes and 37 trimmed.

The largest buyer was Soleus Capital Management, opening a new position worth an estimated $20.3M. The largest seller was Fidelity Investments, cutting an estimated $9.62M.

  • 124 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2023, up from 118 in Q4 2022.
  • Funds reported $149M of Rigel Pharmaceuticals stock for Q1 2023, down 8.9% quarter-over-quarter.
  • 19 funds opened new Rigel Pharmaceuticals positions in Q1 2023 and 12 closed out, a net change of +7 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2023 was Soleus Capital Management, an estimated $20.3M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2023 was Fidelity Investments, an estimated $9.62M sold.

Based on aggregated 13F filings for Q1 2023.